BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,070,990 | -17.0% | 133,260 | -0.5% | 0.01% | -11.1% |
| Q2 2023 | $10,931,358 | +22.7% | 133,913 | +11.5% | 0.01% | +12.5% |
| Q1 2023 | $8,910,751 | -9.6% | 120,107 | +1.0% | 0.01% | -11.1% |
| Q4 2022 | $9,851,775 | +15.9% | 118,868 | +297.3% | 0.01% | 0.0% |
| Q3 2022 | $8,497,000 | -18.1% | 29,917 | -0.1% | 0.01% | -10.0% |
| Q2 2022 | $10,377,000 | -19.6% | 29,934 | +0.5% | 0.01% | -9.1% |
| Q1 2022 | $12,901,000 | -17.3% | 29,793 | -1.3% | 0.01% | -15.4% |
| Q4 2021 | $15,607,000 | +7.3% | 30,171 | +0.6% | 0.01% | 0.0% |
| Q3 2021 | $14,539,000 | +1.9% | 30,004 | -5.3% | 0.01% | 0.0% |
| Q2 2021 | $14,268,000 | +16.7% | 31,686 | -1.0% | 0.01% | +8.3% |
| Q1 2021 | $12,229,000 | -15.2% | 32,021 | -29.5% | 0.01% | -20.0% |
| Q4 2020 | $14,422,000 | +28.8% | 45,412 | +0.4% | 0.02% | +7.1% |
| Q3 2020 | $11,200,000 | -7.1% | 45,209 | -1.0% | 0.01% | -12.5% |
| Q2 2020 | $12,056,000 | +30.3% | 45,654 | -6.4% | 0.02% | +33.3% |
| Q1 2020 | $9,250,000 | -16.0% | 48,782 | -2.7% | 0.01% | +9.1% |
| Q4 2019 | $11,007,000 | +11.7% | 50,140 | -0.5% | 0.01% | +10.0% |
| Q3 2019 | $9,857,000 | +1.5% | 50,379 | +8.1% | 0.01% | 0.0% |
| Q2 2019 | $9,714,000 | +4.0% | 46,590 | -1.0% | 0.01% | +11.1% |
| Q1 2019 | $9,343,000 | +37.3% | 47,057 | +0.1% | 0.01% | +12.5% |
| Q4 2018 | $6,804,000 | -30.0% | 47,018 | -1.3% | 0.01% | -11.1% |
| Q3 2018 | $9,723,000 | +33.9% | 47,636 | -2.9% | 0.01% | +28.6% |
| Q2 2018 | $7,260,000 | -4.4% | 49,061 | -2.4% | 0.01% | 0.0% |
| Q1 2018 | $7,591,000 | +14.4% | 50,251 | -1.9% | 0.01% | +16.7% |
| Q4 2017 | $6,633,000 | -1.3% | 51,200 | -7.9% | 0.01% | -14.3% |
| Q3 2017 | $6,718,000 | +3.4% | 55,567 | +0.5% | 0.01% | 0.0% |
| Q2 2017 | $6,495,000 | +12.7% | 55,287 | -2.5% | 0.01% | +16.7% |
| Q1 2017 | $5,762,000 | -5.1% | 56,679 | -4.1% | 0.01% | -14.3% |
| Q4 2016 | $6,074,000 | -6.3% | 59,082 | -0.2% | 0.01% | -12.5% |
| Q3 2016 | $6,484,000 | -3.8% | 59,207 | -0.9% | 0.01% | 0.0% |
| Q2 2016 | $6,737,000 | -8.9% | 59,748 | -23.6% | 0.01% | -11.1% |
| Q1 2016 | $7,395,000 | +4.4% | 78,231 | -0.6% | 0.01% | +12.5% |
| Q4 2015 | $7,085,000 | -3.9% | 78,719 | -1.2% | 0.01% | -11.1% |
| Q3 2015 | $7,369,000 | -6.9% | 79,703 | -0.9% | 0.01% | 0.0% |
| Q2 2015 | $7,916,000 | -1.8% | 80,391 | -0.0% | 0.01% | 0.0% |
| Q1 2015 | $8,063,000 | +9.6% | 80,395 | +1.0% | 0.01% | +12.5% |
| Q4 2014 | $7,354,000 | – | 79,582 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |